ACE and metabolic bone disorder: These effects were abolished with cotreatment by ACE inhibitors or angiotensin type 1 receptor blockers (ARBs).  These findings are very helpful in targeting RAS as another strategy to treat metabolic bone disorders like osteoporosis.